Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

11-12 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
29/10/26	SEK 0.3755	+1.08%	4,133,745
28/10/26	SEK 0.3715	-3.88%	2,567,496
27/10/26	SEK 0.3865	-7.20%	4,130,881
26/10/26	SEK 0.4165	-1.65%	1,119,099
23/10/26	SEK 0.4235	-0.47%	547,781

Delayed Quote Nasdaq Stockholm

More quotes

EPS Estimates

Evolution of Analysts' Estimates - EPS - Alzinova AB

Revisions to estimates

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Alzinova AB

Company calendar

Market Closed - Nasdaq Stockholm 17:00:00 29/10/2026 GMT			5-day change	1st Jan Change
0.3755 ^SEK	+1.08%		-11.75%	-54.70%

10-21	Alzinova Finalizes US Trial Sites for Mid-stage Alzheimer's Disease Vaccine Study	MT
10-21	Alzinova selects seven U.S. trial sites ahead of phase IIa study	FW

Market Cap	119M 12.04M 10.78M 9.95M 9M 16.83M 1.15B 17.11M 47.35M 600M 45.18M 44.22M 1.9B	P/E 2026 *	-2.68x	P/E 2027 *	-1.39x
Enterprise Value	110M 11.13M 9.96M 9.19M 8.32M 15.56M 1.06B 15.81M 43.76M 554M 41.75M 40.86M 1.76B	EV / Sales 2026 *	3.5x	EV / Sales 2027 *	-
Free-Float	82.68%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	ALZ	Delayed
Deutsche Boerse AG	78D	Delayed
Börse Stuttgart	78D	Delayed
CBOE		Real-time
CBOE		Real-time

10-21	Alzinova Finalizes US Trial Sites for Mid-stage Alzheimer's Disease Vaccine Study	MT
10-21	Alzinova selects seven U.S. trial sites ahead of phase IIa study	FW
10-21	Alzinova AB Finalises Selection Of Seven US Clinical Sites As ADVANCE Phase 2a Study Moves Toward First Participant Enrolment	CI
10-20	Alzinova carries out directed issue worth SEK 3.6m to Mangold	FW
10-15	Calendar Thursday October 15	FW
10-08	Alzinova AB Presents Latest Developments In ALZ-101 And Blood-Based Diagnostics At Redeye Neurology Day	CI
10-08	Redeye reiterates fair value of SEK 0.90 for Alzinova following rights issue	FW
10-08	Alzinova's rights issue subscribed to 86.2 percent, raises SEK 44m	FW
10-07	RX Securities reiterates Buy on Alzinova, cuts fair value to SEK 2.50	FW
10-07	Alzinova Announces Preliminary Outcome Of The Rights Issue	RE
10-07	Alzinova's rights issue subscribed to just over 80 percent	FW
10-02	Alzinova Broadens Shareholder Base With New Investor	RE
10-02	Alzinova's main shareholder sells shares for SEK6.5m, subscribes to its pro rata portion of the offering	FW

Alzinova AB Share Price

Stocks

ALZ

SE0007413455

Biotechnology & Medical Research

Valuation: Alzinova AB

Chart: Alzinova AB

Latest news: Alzinova AB

Analysts' recommendations: Alzinova AB

Press Releases: Alzinova AB

Quotes and Performance

Price Extremes

Managers and Directors: Alzinova AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

10-08	Alzinova: Rights issue subscribed to 86.2%	AQ
10-08	Alzinova to present latest developments in ALZ-101 and blood-based diagnostics at Redeye Neurology Day	AQ
10-08	Alzinova: Rights issue completed	AQ
10-07	Alzinova announces final outcome of the rights issue	AQ
10-06	Alzinova announces preliminary outcome of the rights issue	AQ

1 day	+1.08%
1 week	-11.75%
Current month	-10.38%
1 month	-9.30%
3 months	-61.61%
6 months	-16.56%
Current year	-54.70%

1 week	0.34	0.42
1 month	0.34	0.49
Current year	0.34	1.61
1 year	0.34	2.07
3 years	0.34	4.62
5 years	0.34	7.74
10 years	0.34	44.9

Manager	Title	Age	Since
Tord Labuda CEO	Chief Executive Officer	59	30/09/2024
Anders Sandberg COO	Chief Operating Officer	54	16/08/2011
Erik Kullgren DFI	Director of Finance/CFO	57	26/03/2024

Director	Title	Age	Since
Clas Malmeström BRD	Director/Board Member	61	31/08/2015
Anders Waas BRD	Director/Board Member	69	31/12/2017
Carol Routledge BRD	Director/Board Member	65	31/12/2017

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZINOVA AB	+1.08%	-11.75%	-75.49%	-85.22%	11.84M
WUXI APPTEC CO., LTD.	+0.34%	+1.12%	+34.75%	+61.06%	64.14B
ARGENX SE	+0.98%	+2.68%	+12.25%	+82.98%	55.53B
LONZA GROUP AG	+1.75%	+2.01%	+13.30%	+103.69%	53.03B
IQVIA HOLDINGS INC.	-1.43%	-1.17%	+26.27%	+52.86%	45.99B
BEONE MEDICINES AG	-0.48%	-2.80%	+18.01%	+117.99%	42.45B
REVOLUTION MEDICINES, INC.	+0.82%	+1.37%	+227.94%	+922.41%	40.45B
CELLTRION, INC.	-0.26%	-2.57%	+12.55%	+45.18%	32.25B
GENMAB A/S	-2.07%	+42.73%	+103.77%	+88.74%	34.47B
WUXI BIOLOGICS (CAYMAN) INC.	-1.20%	-3.28%	+21.10%	-12.28%	24.23B
Average	-0.10%	+2.73%	+39.45%	+137.74%	39.26B
Weighted average by Cap.	-0.01%	+3.59%	+49.16%	+160.47%

	2026 *	2027 *
Net sales	31.35M 3.18M 2.85M 2.63M 2.38M 4.45M 303M 4.52M 12.51M 158M 11.93M 11.68M 502M	-
Net income	1.55M 157K 141K 130K 118K 220K 14.97M 223K 618K 7.84M 590K 577K 24.82M	-84M -8.52M -7.63M -7.04M -6.37M -11.91M -811M -12.11M -33.51M -425M -31.98M -31.3M -1.34B
Net Debt	-9M -913K -818K -754K -683K -1.28M -86.93M -1.3M -3.59M -45.5M -3.43M -3.35M -144M	-4M -406K -363K -335K -303K -567K -38.64M -577K -1.6M -20.22M -1.52M -1.49M -64.04M